Cargando…

F163. STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE BRAIN DURING WORKING MEMORY IN MEDICATION-NAïVE PATIENTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS

BACKGROUND: The pre-TIPS study in 1994–95 showed that the duration of untreated psychosis (DUP) was long in our region with a mean value of 2.1 years, and median 26 weeks. This set the stage for the TIPS-study (1997–2000), reducing DUP through information campaigns targeted to the general population...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brønnick, Kolbjørn, Gisselgård, Jens, Joa, Inge, Ingvild, Aase, Jørgensen, Robert, Johannessen, Jan Olav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888553/ http://dx.doi.org/10.1093/schbul/sby017.694

Ejemplares similares

Structural and functional alterations in the brain during working memory in medication-naïve patients at clinical high-risk for psychosis
por: Gisselgård, Jens, et al.
Publicado: (2018)

Language Lateralization and Auditory Attention Impairment in Young Adults at Ultra-High Risk for Psychosis: A Dichotic Listening Study
por: Aase, Ingvild, et al.
Publicado: (2018)

Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian Ultra High Risk study
por: Joa, Inge, et al.
Publicado: (2015)

Visual Hallucinations in First-Episode Psychosis: Association with Childhood Trauma
por: Solesvik, Martine, et al.
Publicado: (2016)

T165. ULTRA-HIGH FIELD MORPHOMETRY IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS
por: Das, Tushar, et al.
Publicado: (2018)

S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAïVE AND PREVIOUSLY MEDICATED PATIENTS
por: Stabell, Lena, et al.
Publicado: (2018)

Associations between symptom and neurocognitive dimensions in clinical high risk for psychosis
por: Aase, Ingvild, et al.
Publicado: (2022)

Cognitive predictors of longitudinal positive symptom course in clinical high risk for psychosis
por: Aase, Ingvild, et al.
Publicado: (2021)

T164. STRUCTURAL COVARIANCE IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS: AN ULTRA-HIGH FIELD MRI STUDY
por: Das, Tushar, et al.
Publicado: (2018)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms
por: Anda, Liss, et al.
Publicado: (2019)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

S234. ONE-YEAR OUTCOME AND USE OF CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA
por: Drosos, Petros, et al.
Publicado: (2018)

Psychiatric patients’ attitudes towards being hospitalized: a national multicentre study in Norway
por: Hustoft, Kjetil, et al.
Publicado: (2022)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

S150. DOPAMINE SYNTHESIS CAPACITY IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOTIC PATIENTS
por: Sigvard, Anne, et al.
Publicado: (2018)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

F181. CHANGE IN PREFRONTAL-LIMBIC MORPHOLOGY AND COGNITION IN DRUG-NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS FOLLOWING ATYPICAL ANTIPSYCHOTIC TREATMENT: A BRIEF LONGITUDINAL STUDY
por: Woodward, Melissa, et al.
Publicado: (2018)

T25. ALTERATIONS OF PLASMA PHOSPHOLIPID FATTY ACID PROFILES ARE ASSOCIATED WITH LOCAL BRAIN STRUCTURAL ABNORMALITIES IN NEUROLEPTIC NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS
por: Langbein, Kerstin, et al.
Publicado: (2018)

O6.3. PATTERNS OF GRAY MATTER ABNORMALITIES IN PATIENTS WITH FIRST-EPISODE AND TREATMENT-NAïVE SCHIZOPHRENIA
por: Li, Mingli, et al.
Publicado: (2018)

“Everyone Needs a Friend Sometimes” – Social Predictors of Long-Term Remission In First Episode Psychosis
por: Bjornestad, Jone, et al.
Publicado: (2016)

F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS
por: Bojesen, Kirsten, et al.
Publicado: (2018)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results From a Consecutive Cohort Study
por: Drosos, Petros, et al.
Publicado: (2020)

T98. THE EFFECT OF SUBSTANCE USE ON 10-YEAR OUTCOME IN FIRST EPISODE PSYCHOSIS – EARLY CESSATION RESULTS IN BETTER OUTCOMES
por: Weibell, Melissa, et al.
Publicado: (2018)

Early Substance Use Cessation Improves Cognition—10 Years Outcome in First-Episode Psychosis Patients
por: Weibell, Melissa A., et al.
Publicado: (2019)

The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement
por: Anda, Liss, et al.
Publicado: (2016)

F206. A TRANSLATIONAL STUDY OF BEHAVIOR, BRAIN STRUCTURE AND GENE PATHWAY IN ERBB4 KNOCKOUT MICE AND FIRST-EPISODE TREATMENT-NAïVE PATIENTS WITH SCHIZOPHRENIA
por: Zhang, Chengcheng, et al.
Publicado: (2018)

O3.8. DORSOLATERAL PREFRONTAL CORTEX IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA: DYNAMIC PHASE COHERENCE OF INFRASLOW OSCILLATIONS
por: Das, Tushar, et al.
Publicado: (2018)

S209. DRUG-NAïVE FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS: PHARMACOLOGICAL TREATMENT PRACTICES IN INPATIENT UNITS IN HUNAN PROVINCE, CHINA
por: Zhu, Mengran, et al.
Publicado: (2020)

Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study
por: Yeisen, Rafal A. H., et al.
Publicado: (2017)

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
por: Jessen, Kasper, et al.
Publicado: (2018)

T23. DYNAMICS OF NEURONAL METABOLISM AFTER THE ACUTE ONSET OF PSYCHOSIS – A TWO YEARS FOLLOW-UP 1H/31P-MR-SPECTROSCOPY STUDY IN NEUROLEPTIC NAïVE UHR TRANSITION PATIENTS
por: Smesny, Stefan, et al.
Publicado: (2018)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

Early Detection of Ultra High Risk for Psychosis in a Norwegian Catchment Area: The Two Year Follow-Up of the Prevention of Psychosis Study
por: Joa, Inge, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hpkufgk58gpuhev7p6d1choit